Answers are grounded in this paper and cite their sources.
Background: Methoxyflurane administered via an inhaler is a common analgesic agent used by ambulance services in Australia; however little published data exists as to its efficacy or effectiveness in this setting. There have been several reports that have suggested that the use of Methoxyflurane may be associated with the occurrence of hepatitis and renal disease. Such concerns have led to an increasing reluctance to use Methoxyflurane as an analgesic agent in the prehospital setting. The aim of this study was to determine whether the event rates of heart disease, renal disease, hepatic disease, diabetes or cancer in patients who received Methoxyflurane compared with those not receiving Methoxyflurane prehospital.
No takes yet. Share an insight, caveat, or question.
Ian Jacobs (2010) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: